Julie N Graff1, Celestia S Higano2, Noah M Hahn3, Matthew H Taylor1, Bin Zhang4, Xiaofei Zhou4, Karthik Venkatakrishnan4, E Jane Leonard4, John Sarantopoulos5. 1. Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. 2. Fred Hutchinson Cancer Research Center, Seattle, Washington. 3. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland. 4. Millennium Pharmaceuticals, Inc, Takeda Pharmaceutical Company, Limited, Cambridge, Massachusetts. 5. Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, Texas.
Abstract
BACKGROUND: This study was designed to determine the safety, tolerability, and pharmacokinetics (PK) of alisertib (MLN8237) in combination with docetaxel and to identify a recommended dose for the combination. METHODS: Adults with metastatic cancer were treated on 21-day cycles with alisertib (10, 20, 30, or 40 mg) twice daily on days 1 to 7 or days 1 to 5 and with docetaxel (75 or 60 mg/m(2) ) on day 1. The primary objectives were to assess the safety and tolerability of the combination and to determine the recommended phase 2 dose (RP2D) for future studies. Secondary objectives included an efficacy assessment and PK analyses of docetaxel and alisertib. RESULTS: Forty-one patients participated. Eight dose levels were explored with various doses of alisertib and docetaxel. The dose-limiting toxicities were neutropenic fever, neutropenia without fever, stomatitis, and urinary tract infection. The RP2D of this combination was 20 mg of alisertib twice daily on days 1 to 7 and intravenous docetaxel at 75 mg/m(2) on day 1 in 21-day cycles. Eight of the 28 patients (29%) who were efficacy-evaluable had objective responses. These included 1 complete response in a patient with bladder cancer, 6 partial responses in patients with castration-resistant prostate cancer, and 1 partial response in a patient with angiosarcoma. Concomitant administration of alisertib did not produce any clinically meaningful change in docetaxel PK. CONCLUSIONS: Alisertib at 20 mg twice daily on days 1 to 7 with intravenous docetaxel at 75 mg/m(2) on day 1 in a 21-day cycle was well tolerated, and the combination demonstrated antitumor activity. Cancer 2016;122:2524-33.
BACKGROUND: This study was designed to determine the safety, tolerability, and pharmacokinetics (PK) of alisertib (MLN8237) in combination with docetaxel and to identify a recommended dose for the combination. METHODS: Adults with metastatic cancer were treated on 21-day cycles with alisertib (10, 20, 30, or 40 mg) twice daily on days 1 to 7 or days 1 to 5 and with docetaxel (75 or 60 mg/m(2) ) on day 1. The primary objectives were to assess the safety and tolerability of the combination and to determine the recommended phase 2 dose (RP2D) for future studies. Secondary objectives included an efficacy assessment and PK analyses of docetaxel and alisertib. RESULTS: Forty-one patients participated. Eight dose levels were explored with various doses of alisertib and docetaxel. The dose-limiting toxicities were neutropenic fever, neutropenia without fever, stomatitis, and urinary tract infection. The RP2D of this combination was 20 mg of alisertib twice daily on days 1 to 7 and intravenous docetaxel at 75 mg/m(2) on day 1 in 21-day cycles. Eight of the 28 patients (29%) who were efficacy-evaluable had objective responses. These included 1 complete response in a patient with bladder cancer, 6 partial responses in patients with castration-resistant prostate cancer, and 1 partial response in a patient with angiosarcoma. Concomitant administration of alisertib did not produce any clinically meaningful change in docetaxel PK. CONCLUSIONS:Alisertib at 20 mg twice daily on days 1 to 7 with intravenous docetaxel at 75 mg/m(2) on day 1 in a 21-day cycle was well tolerated, and the combination demonstrated antitumor activity. Cancer 2016;122:2524-33.
Authors: Laura W Goff; Nilofer S Azad; Stacey Stein; Jennifer G Whisenant; Tatsuki Koyama; Ulka Vaishampayan; Howard Hochster; Roisin Connolly; Amy Weise; Patricia M LoRusso; Safia N Salaria; Wael El-Rifai; Jordan D Berlin Journal: Invest New Drugs Date: 2018-09-06 Impact factor: 3.850
Authors: Cory T Zumbar; Aisulu Usubalieva; Paul D King; Xiaohui Li; Caroline S Mifsud; Hailey M Dalton; Muge Sak; Sara Urio; William M Bryant; Joseph P McElroy; George Farmer; Norman L Lehman Journal: J Neurooncol Date: 2018-02-02 Impact factor: 4.130
Authors: Gerald Falchook; Robert L Coleman; Andrzej Roszak; Kian Behbakht; Ursula Matulonis; Isabelle Ray-Coquard; Piotr Sawrycki; Linda R Duska; William Tew; Sharad Ghamande; Anne Lesoin; Peter E Schwartz; Joseph Buscema; Michel Fabbro; Alain Lortholary; Barbara Goff; Razelle Kurzrock; Lainie P Martin; Heidi J Gray; Siqing Fu; Emily Sheldon-Waniga; Huamao Mark Lin; Karthik Venkatakrishnan; Xiaofei Zhou; E Jane Leonard; Russell J Schilder Journal: JAMA Oncol Date: 2019-01-10 Impact factor: 31.777
Authors: Tanya Siddiqi; Paul Frankel; Jan H Beumer; Brian F Kiesel; Susan Christner; Chris Ruel; Joo Y Song; Robert Chen; Kevin R Kelly; Sikander Ailawadhi; Paul Kaesberg; Leslie Popplewell; Sandrine Puverel; Richard Piekarz; Stephen J Forman; Edward M Newman Journal: Leuk Lymphoma Date: 2019-10-16
Authors: Thomas J Semrad; Edward J Kim; I-Yeh Gong; Tianhong Li; Scott Christensen; Mili Arora; Jonathan W Riess; David R Gandara; Karen Kelly Journal: Cancer Chemother Pharmacol Date: 2021-05-15 Impact factor: 3.288
Authors: Jelena Belic; Ricarda Graf; Thomas Bauernhofer; Yauheniya Cherkas; Peter Ulz; Julie Waldispuehl-Geigl; Samantha Perakis; Michael Gormley; Jaymala Patel; Weimin Li; Jochen B Geigl; Denis Smirnov; Ellen Heitzer; Mitchell Gross; Michael R Speicher Journal: Int J Cancer Date: 2018-04-10 Impact factor: 7.396
Authors: Xiwei Ding; Tianlu Huang; Chunyan Peng; Keun Soo Ahn; Jesper B Andersen; Monika Lewinska; Yu Cao; Guifang Xu; Gang Chen; Bo Kong; Helmut Friess; Shanshan Shen; Lewis R Roberts; Lei Wang; Xiaoping Zou Journal: J Cancer Date: 2020-02-03 Impact factor: 4.207